Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

454

Participants

Timeline

Start Date

March 4, 2011

Primary Completion Date

February 24, 2012

Study Completion Date

February 24, 2012

Conditions
PoliomyelitisTetanusAcellular PertussisDiphtheriaHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

Infanrix™-IPV+Hib

Intramuscular, 3 doses

BIOLOGICAL

Infanrix™ IPV

Intramuscular, 3 doses

BIOLOGICAL

Hiberix™

Intramuscular, 3 doses

BIOLOGICAL

Synflorix™

Intramuscular, 3 doses

BIOLOGICAL

Rotarix™

Oral, 2 doses

Trial Locations (11)

700-712

GSK Investigational Site, Daegu

Unknown

GSK Investigational Site, Goyang

641-560

GSK Investigational Site, GyeongSangNam-do

570-711

GSK Investigational Site, Iksan

561-712

GSK Investigational Site, Jeonju Jeonbuk

463-712

GSK Investigational Site, Seongnam-si

120-752

GSK Investigational Site, Seoul

139-706

GSK Investigational Site, Seoul

442-723

GSK Investigational Site, Suwon City, Gyeonggi-do

480-717

GSK Investigational Site, Uijeongbu, Gyeonggi-do

220-701

GSK Investigational Site, Wonju-si Kangwon-do

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY